Biotechnology R&D · global
Dong-A ST Teams Up with Galux to Design New Antibodies and Explore a New Target for Cancer ADCs
The collaboration will design antibodies based on protein structure, then assess whether they can be linked to anticancer drugs. The first test for this research is to establish whether an undisclosed new target is suitable for ADC development; no efficacy or safety data for drug candidates are available yet.
Antibodies that recognize their targets are a key component in getting anticancer drugs to tumors. South Korean pharmaceutical company Dong-A ST and AI protein design company Galux announced a research collaboration on October 1, 2026, to design new antibodies from scratch and explore whether a new target with no approved therapies could serve as a starting point for developing antibody-drug conjugates (ADCs).
According to Galux’s announcement, the companies’ current task is to identify candidate molecules and validate the feasibility of development. The announcement did not disclose the target’s name or the cancer types intended for treatment. Therefore, “no approved therapies” refers to the target’s development status and cannot be taken to mean that patients with the relevant cancers have no treatment options at all.
ADCs consist of an antibody, a linker, and a drug payload: the antibody recognizes a specific target, while the linker connects the antibody to a drug that kills cancer cells. This makes antibody selection particularly important—both its ability to recognize the target and the overall molecule’s ability to deliver the drug effectively will influence the value of further development.
Galux will use its proprietary GaluxDesign platform to generate antibody candidates through de novo design based on the target protein’s structure, function, and interactions. AI’s specific role here is to propose new antibody designs suited to recognizing the target; the research does not merely modify existing antibodies, nor has it established that these designs will be effective against cancer once linked to drugs.
Dong-A ST will undertake the next stage of validation. News1 and ChosunBiz reported that Dong-A ST will draw on its ADC platform and experience in linker and drug payload development to assess whether the antibodies are suitable for use in ADCs and advance subsequent candidate development. Galux’s announcement stated that the companies will explore further development of selected molecules; how far the collaboration can proceed still depends on the results of this round of research.
Publicly available information currently provides no antibody-binding data or cell or animal study results from this collaboration, nor does it specify the AI training data, design success rate, or timeline for entering human trials. The companies’ stated ambition to be “best-in-class” is a development goal, with no comparative evidence yet to support it. This collaboration offers a research path toward identifying new ADCs; actual progress will gradually become clearer as the designed molecules undergo experimental testing and evidence of efficacy and safety begins to accumulate.